When Phlebotomy Isn't an Option: Chelation for a Patient Who Can't Give Blood
A hemochromatosis patient can't tolerate phlebotomy because of a concurrent anemia, and iron continues to accumulate. Before the team reaches for a chelator built for a different population, someone has to ask whether the anemia itself has actually been worked up.
Gordon B., a 71-year-old man, has restored antique clocks out of his home workshop since retiring from an accounting career eight years ago, a hobby his late wife used to tease him about taking too seriously. He was diagnosed with hereditary hemochromatosis fifteen years ago, homozygous for the C282Y HFE mutation, and maintained on regular phlebotomy until roughly a year ago, when a progressively worsening anemia — never fully characterized, attributed loosely at the time to 'age-related' causes — made continued blood draws impractical without pushing his hemoglobin dangerously low. His ferritin, well-controlled for over a decade on phlebotomy, has since climbed from 180 to 640, and his most recent liver MRI shows rising hepatic iron concentration consistent with re-accumulation.
Iron chelation, most established in transfusion-dependent iron-overload populations such as thalassemia or myelodysplastic syndrome, is the pharmacologic option left once phlebotomy is genuinely off the table — but Gordon isn't transfusion-dependent, and the safety data behind deferasirox comes almost entirely from a population whose kidneys and livers were being studied under a different set of baseline conditions than his. The one dedicated trial in his own disease — Phatak's dose-ranging study of deferasirox in HFE hemochromatosis — was small, ran a year, and was powered to show ferritin fell, not to establish renal safety over the years of exposure he is actually facing. Whether chelation is actually the right substitute, or whether the more basic question of what's causing his anemia in the first place still needs an answer before either option is finalized, is where the team has landed.
What hasn't been asked yet
His ferritin has more than tripled and his liver iron is climbing again. I'd start deferasirox — it's the pharmacologic option available once phlebotomy is genuinely off the table, and continued iron accumulation carries its own real, well-established organ-damage risk that doesn't pause while we sort out the anemia.
I'd slow down before committing to that. Deferasirox's own safety data — the renal and hepatic toxicity signals specifically — comes almost entirely from transfusion-dependent populations like thalassemia and MDS. Gordon isn't transfusion-dependent, and his eGFR is already mildly reduced. Extrapolating a safety profile built in a genuinely different population to him isn't automatically wrong, but it's a real gap, not a formality to note and move past.
'Continued accumulation carries its own risk' is true, but it doesn't tell us chelation is the lower-risk option for him specifically — that's exactly the comparison the population mismatch makes harder to make confidently.
Before either of you finalizes a chelation plan, I'd want to know why this conversation is happening at all. His anemia was attributed to 'age-related causes' a year ago and never actually characterized — no reticulocyte count, no iron studies beyond what hemochromatosis monitoring already tracks, no bone marrow evaluation. If this is something reversible, treating it could restore his ability to tolerate phlebotomy directly, which sidesteps the entire chelation question rather than answering it. I'd get a real hematology workup before we commit him to a drug whose safety data doesn't cleanly apply to him.
No chelation started today. A formal hematology workup was ordered to characterize the previously unexplained anemia before any decision about substituting a pharmacologic option for phlebotomy.
The hepatologist's underlying concern about ongoing iron accumulation was documented as active and unresolved, with a plan to revisit chelation directly if the workup doesn't identify a reversible cause.